HOME >> BIOLOGY >> NEWS
Blood test shows promise as monitor for antiangiogenic cancer therapy

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies. The research, published in the January issue of Cancer Cell, is likely to facilitate development of new antiangiogenic drugs or treatment strategies and allow for accurate determination of the optimal drug doses to use for such therapies.

Antiangiogenic cancer therapy targets the formation of new blood vessels used to support tumor growth. Although many of these agents are currently being tested in clinical trials, no reliable way to monitor the effects of many, if not most, of these therapeutic agents on the inhibition of the complicated process of angiogenesis exists. Dr. Robert S. Kerbel from Women's College Health Sciences Centre in Toronto and colleagues, including Dr. Francesco Bertolini of the European Institute of Oncology in Milan and Dr. Robert D'Amato of Harvard University, examined whether circulating levels of a class of specific blood cells that contribute to the formation of tumor vessels provide any useful information about the effectiveness of angiogenesis inhibitors.

The researchers found that levels of circulating endothelial cells (CECs) and circulating endothelial progenitor cells (CEPs) are quite varied depending on the genetic background of an animal. However, within a particular strain of mice, levels of these cells are influenced by known regulators of blood vessel formation and correlate remarkably with the ability to induce tumor blood vessel growth and the response to antiangiogenic therapy. Importantly, treatment with a drug that interfered with the major signaling receptor for vascular endothelial growth factor (VEGF), a key regulator of blood vessel development, caused a dose-dependent reduction in CEPs. The reduction in CEPs closely reflected the previously established antitumor activity of this VEGF inhibitor, and the optimal decline in CECs and CEPs was reached
'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2879
Cell Press
17-Jan-2005


Page: 1 2

Related biology news :

1. Blood test may help signal tumors remission, return in throat cancer patients
2. Blood sugars manufacture limited by building blocks supply
3. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
4. Blood tests may be possible for mental health conditions
5. Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology
6. Blood test predicts cardiac events and death in heart patients
7. Blood clot fibers more elastic than spiders web
8. Blood-compatible nanoscale materials possible using heparin
9. Blood pressure medication may revolutionize treatment of Marfan syndrome
10. Blood levels of suspected carcinogen vary by race, ethnicity
11. Blood conservation strategies take center stage at Emory University Hospital forum

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... June 04, 2019 , ... In’Tech ... devices, today announced Q1-19 revenues of $31M, up 12% from Q1-18. The growth ... of strategic investments & operational excellence initiatives worldwide. , Laurent Pruvost , ...
(Date:6/4/2019)... , ... June 04, 2019 , ... Harper was three ... X-rays revealed severe elbow dysplasia, which caused painful osteoarthritis in the joints. ... Her parents were heartbroken. , The surgical specialist, Dr. Christopher Eich of ...
(Date:6/4/2019)... SAN DIEGO (PRWEB) , ... June 04, 2019 , ... ... Hall of Fame recipients. The recognition, which honors hospitality excellence, is given only to ... a Certificate of Excellence for five consecutive years. , To qualify for ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... ... 03, 2019 , ... More than three thousand people participated ... scientist and ufologist Urandir Fernandes de Oliveira, last Thursday (25), during the XVIII ... some research carried out by the association, in partnership with scientists from Brazil ...
(Date:5/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by ... is free, so be sure to register today to save your place! Participate in ... see our upcoming webinars: , CLINICAL TRIALS , May 7 – Oncology Clinical Trials ...
(Date:4/25/2019)... ... April 24, 2019 , ... ... sales and service organizations, today announced global availability of Inference Studio’s latest version, ... of all sizes to harness the power of Google’s Contact Center AI ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., ... $2 million bench plant expansion to increase production of methylene malonate monomers and ... and construction of Sirrus’ full-scale production facility, which is scheduled to break ground ...
Breaking Biology Technology:
Cached News: